Advanced clinical medicine for USMLE Step 3

A 54-year-old woman on your panel has an LDL of 168 mg/dL, blood pressure 138/84 mmHg, is a non-smoker and has no diabetes. Her 10-year ASCVD risk is 9.2%. She is unsure about starting a statin. What is the most appropriate management?

1. Engage in a risk discussion and offer a moderate-intensity statin, considering coronary artery calcium scoring if she remains undecided correct Correct. She is in the intermediate-risk band, where guidelines call for a clinician–patient risk discussion rather than an automatic prescription, and coronary artery calcium scoring is the recognized tiebreaker.
2. Lifestyle modification alone and recheck in 5 years Too passive. A 9.2% ten-year risk with an LDL of 168 warrants an active conversation now, and five years is far too long.
3. Order a PCSK9 inhibitor Reserved for very high-risk patients or familial hypercholesterolemia inadequately controlled on maximally tolerated statin plus ezetimibe.
4. Start ezetimibe as first-line therapy Ezetimibe is add-on therapy when a statin is insufficient or not tolerated.
5. Start high-intensity statin therapy immediately without further discussion Wrong intensity and wrong process. High-intensity statins are for clinical ASCVD, LDL at or above 190, or high estimated risk.

The point: ASCVD primary prevention bands: below 5% low, 5 to 7.4% borderline, 7.5 to 19.9% intermediate (risk discussion, moderate-intensity statin, CAC if undecided), 20% or above high. Step 3 tests the conversation as much as the drug.

Source: ACC/AHA guideline on the primary prevention of cardiovascular disease American College of Cardiology / AHA · tier 2, specialty society or college

A 66-year-old man with COPD, heart failure with reduced ejection fraction and stage 3 chronic kidney disease has been admitted three times in six months. He lives alone, takes 14 medications, and admits he sometimes cannot remember whether he has taken them. Which intervention is most likely to reduce his readmission rate?

1. A structured transition-of-care program with medication reconciliation, early follow-up and a written care plan correct Correct. The strongest evidence for reducing readmissions in complex multimorbid patients comes from structured transitional care: reconciling medications at every handoff, arranging follow-up within about a week, providing a written plan the patient can follow, and giving a clear route to call before deteriorating.
2. Increasing the diuretic dose empirically at discharge Treats one condition in isolation, and empirically escalating diuretics in stage 3 chronic kidney disease risks acute kidney injury and another admission.
3. Referral for pulmonary rehabilitation alone Genuinely valuable in COPD and worth arranging, but it addresses one of his three conditions and not the medication and coordination problem driving the cycle.
4. Adding a home oxygen concentrator Only indicated if he meets criteria on arterial blood gas measurement. Prescribing it without indication provides no benefit and introduces hazards.
5. Scheduling a follow-up appointment in three months Too late to influence the highest-risk window, which is the first 7 to 30 days after discharge.

The point: Step 3 tests systems thinking as well as disease. Readmission reduction comes from medication reconciliation, prompt follow-up, a written plan in plain language, involving carers, and addressing social determinants. Polypharmacy in multimorbidity is itself a treatable problem.

Source: AHRQ — care transitions and readmission reduction resources AHRQ · tier 1, national regulator or guidance

A 46-year-old man with alcohol use disorder is admitted with pancreatitis. On day 3 he is medically improving and asks for help with drinking. He has no liver failure and normal renal function. Which pharmacologic option has the best evidence for maintaining abstinence in this patient?

1. Gabapentin as the established first-line agent Has some supporting evidence and a role, particularly where there is coexisting neuropathic pain or insomnia, but it is not the best-evidenced first-line choice.
2. Chlordiazepoxide continued long term after discharge Wrong. Benzodiazepines treat acute withdrawal over days, not long-term abstinence, and continuing them creates dependence.
3. Naltrexone correct Correct. Naltrexone has good evidence for reducing heavy drinking and relapse, and it can be started while the patient is still an inpatient. It is contraindicated with opioid use and in acute hepatitis or liver failure, neither of which applies here.
4. No pharmacotherapy — counseling alone is sufficient Wrong. Combining pharmacotherapy with psychosocial support outperforms either alone, and the moment a patient asks for help is the moment to act.
5. Disulfiram as first-line therapy Depends heavily on supervised administration and motivation, and it carries a risk of severe reactions. It is not first line.

The point: Alcohol use disorder pharmacotherapy: naltrexone and acamprosate first line, disulfiram in selected supervised patients, topiramate and gabapentin as alternatives. Acamprosate is preferred in liver disease; naltrexone is avoided with opioids. Start it during the admission, waiting for outpatient follow-up loses most patients.

Source: APA practice guideline for the pharmacological treatment of patients with alcohol use disorder American Psychiatric Association · tier 2, specialty society or college